Investigators found data from the National Notifiable Diseases Surveillance System that showed hepatitis C virus infection rates doubled among women of reproductive age between 2006 and 2014.
Further patient advocacy is needed to ensure that recipients of HCV-infected organs have access to direct-acting antivirals as early as possible, including in a prophylactic manner, if data continue to support its benefit.
Although hepatic vein pressure gradient measurement is an accurate method for evaluation of portal HTN, this technique is invasive and not widely available.
The opioid epidemic has fueled the transmission of HCV, particularly among younger persons, who are often unaware of their risks and prevented from receiving timely treatment due to a variety of care barriers, even in settings ideally suited to identifying and treating HCV.
A combined hepatitis A and typhus vaccine in Australia for use in patients aged > 16 years was shown to be well-tolerated in children aged 2 to 16 years.
In parallel to the ongoing national opioid crisis, the incidence rate of infective endocarditis cases has increased markedly among people aged 18 to 29 years with hepatitis C virus infection and those with opioid use disorder.
New polices, including testing for hepatitis C virus (HCV) during pregnancy, may increase HCV identification in the pediatric population by addressing gaps in maternal HCV testing.
Patients with chronic hepatitis C (HCV) achieving sustained virologic response to pegylated interferon plus ribavirin therapy did not exhibit an effect on the incidence of systemic lupus erythematosus (SLE) or rheumatoid arthritis.
Compared with all opioid prescriptions, a higher hydromorphone controlled-release dispensing rate was a strong predictor of hepatitis C virus incidence.
Next-generation sequencing is an important tool that can help differentiate HCV reinfection from treatment failure, and may assist with the design of targeted prevention strategies in PWID receiving opioid agonist therapy.
Patients with HIV and those with a history of intravenous drug use may have significantly higher rates of hepatic steatosis, according to research results presented at the virtual Conference on Retroviruses and Opportunistic Infections, held from March 8 to 11, 2020. Two groups of researchers examined the role of hepatic steatosis across these patient populations.…
A study identifies risk factors for hepatocellular carcinoma (HCC) after the first 5 years of receiving antiviral therapy in white patients with chronic hepatitis B.
Among patients coinfected with HIV/HCV, there were no medium-term beneficial effects of sustained virologic response on markers of preclinical atherosclerosis and biomarkers of inflammation and endothelial dysfunction.
Primary vaccination against hepatitis B virus (HBV) at birth may not provide adequate lifelong antibody levels, but a booster vaccine at age 18 years reinforces antibody levels for at least 4 more years.
In patients coinfected with HIV and HCV, eradication of HCV had no effect on markers of preclinical atherosclerosis and biomarkers of inflammation and endothelial dysfunction.
The study researchers concluded that different DAA therapies may be safely used with high SVR12 rates in patients with HCV and GFR less than 30 ml/min, except for ribavirin due to poor tolerability.
